Cytokinetics (CYTK) Short term Debt (2016 - 2025)
Historic Short term Debt for Cytokinetics (CYTK) over the last 12 years, with Q3 2024 value amounting to $12.5 million.
- Cytokinetics' Short term Debt changed N/A to $12.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $12.5 million, marking a year-over-year change of. This contributed to the annual value of $10.1 million for FY2023, which is 95219.21% up from last year.
- Per Cytokinetics' latest filing, its Short term Debt stood at $12.5 million for Q3 2024.
- Cytokinetics' Short term Debt's 5-year high stood at $16.9 million during Q3 2021, with a 5-year trough of $958000.0 in Q4 2022.
- Moreover, its 4-year median value for Short term Debt was $11.4 million (2021), whereas its average is $10.3 million.
- The largest annual percentage gain for Cytokinetics' Short term Debt in the last 5 years was 95219.21% (2023), contrasted with its biggest fall of 95219.21% (2023).
- Over the past 4 years, Cytokinetics' Short term Debt (Quarter) stood at $16.9 million in 2021, then tumbled by 94.32% to $958000.0 in 2022, then skyrocketed by 952.19% to $10.1 million in 2023, then rose by 24.01% to $12.5 million in 2024.
- Its Short term Debt stands at $12.5 million for Q3 2024, versus $13.2 million for Q2 2024 and $11.5 million for Q1 2024.